Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
| ▸ | NAAA | Q02083 | 4/20 | 0.42 |
| ▸ | TACR1 | P25103 | 2/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | LTA4H | P09960 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | TEAD3 | Q99594 | 1/20 | 0.39 |
| ▸ | AGXT | P21549 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL29284774 | 0.98 | TSHR (0.52) | TSHRTDP1L3MBTL1HRH4HRH3 | |
| SCHEMBL5717211 | 0.94 | TSHR (0.52) | TSHRTDP1L3MBTL1HRH4HRH3 | |
| SCHEMBL14128885 | 0.90 | TSHR (0.56) | TSHRTDP1L3MBTL1HRH4HRH3 | |
| SCHEMBL10169910 | 0.83 | TSHR (0.36) | TSHRTDP1L3MBTL1HRH4HRH3 | |
| SCHEMBL8621469 | 0.83 | TSHR (0.70) | TSHRTDP1L3MBTL1HRH4HRH3 | |
| SCHEMBL2640223 | 0.83 | TSHR (0.70) | TSHRTDP1L3MBTL1HRH4HRH3 | |
| SCHEMBL9011734 | 0.81 | TSHR (0.67) | TSHRTDP1L3MBTL1HRH4HRH3 | |
| SCHEMBL9011595 | 0.81 | TSHR (0.67) | TSHRTDP1L3MBTL1HRH4HRH3 | |
| SCHEMBL9011715 | 0.81 | TSHR (0.67) | TSHRTDP1L3MBTL1HRH4HRH3 | |
| SCHEMBL9011624 | 0.81 | TSHR (0.67) | TSHRTDP1L3MBTL1HRH4HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250288683-A1 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | Treeline Biosciences, Inc. | 2025-09-18 | — | — | US | disclosed |
| US-20250282771-A1 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | Treeline Biosciences, Inc. | 2025-09-11 | — | — | US | disclosed |
| WO-2025101588-A1 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | Treeline Biosciences, Inc. (US) | 2025-05-15 | — | — | WO | disclosed |
| EP-4519272-A1 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | Treeline Biosciences, Inc. (US) | 2025-03-12 | — | — | EP | disclosed |
| EP-4519260-A1 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XDEGRADERS | Treeline Biosciences, Inc. (US) | 2025-03-12 | — | — | EP | disclosed |
| EP-4519259-A1 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | Treeline Biosciences, Inc. (US) | 2025-03-12 | — | — | EP | disclosed |
| US-20240238423-A9 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | Treeline Biosciences, Inc. | 2024-07-18 | — | — | US | disclosed |
| US-20230390404-A1 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | TREELINE BIOSCIENCES INC (US) | 2023-12-07 | — | — | US | disclosed |
| WO-2023215482-A1 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | Treeline Biosciences, Inc. (US) | 2023-11-09 | — | — | WO | disclosed |
| WO-2023215449-A1 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | Treeline Biosciences, Inc. (US) | 2023-11-09 | — | — | WO | disclosed |
| US-8106095-B2 | modulators of peroxisome proliferator activated receptors; treating diabetes, polycystic ovary syndrome, hypertension, ischemia, stroke, irritable bowel disorder, inflammation, cardiovascular diseases; dyslipidema; [4-[[2-ethoxy-3-[4-(trifluoromethyl)phenoxy]propyl]thio]-2-methylphenoxy]-acetic acid | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-01-31 | — | — | US | disclosed |
| US-20100069496-A1 | 4-((PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS | CYMABAY THERAPEUTICS, INC. | 2010-03-18 | — | — | US | disclosed |
| EP-1318993-B1 | SUBSTITUTED IMIDAZOLES AS DUAL HISTAMINE H1 AND H3 AGONISTS OR ANTAGONISTS | SCHERING CORP (US) | 2008-08-20 | — | — | EP | disclosed |
| US-7307098-B2 | Indole derivatives and drugs containing the same | MEIJI DAIRIES CORPORATION (JP) | 2007-12-11 | — | — | US | disclosed |
| US-20070142397-A2 | PHENYPIPERAZINE DERIVATIVES WITH A COMBINATION OF PARTIAL DOPAMINE-D2 RECEPTOR AGONISM AND SEROTONIN REUPTAKE INHIBITION | SOLVAY PHARMECEUTICALS B.V. (NL) | 2007-06-21 | — | — | US | disclosed |
| EP-0950047-B1 | INDOLIN-2-ONE DERIVATIVES, METHOD FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SANOFI SYNTHELABO (FR) | 2003-10-15 | — | — | EP | disclosed |
| EP-1318993-A2 | SUBSTITUTED IMIDAZOLES AS DUAL HISTAMINE H1 AND H3 AGONISTS OR ANTAGONISTS | Schering Corporation (US) | 2003-06-18 | — | — | EP | disclosed |
| WO-2002024657-A2 | SUBSTITUTED IMIDAZOLES AS DUAL HISTAMINE H1 AND H3 AGONISTS OR ANTAGONISTS | SCHERING CORPORATION (US) | 2002-03-28 | — | — | WO | disclosed |
| EP-0950047-A1 | INDOLIN-2-ONE DERIVATIVES, METHOD FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SANOFI-SYNTHELABO (FR) | 1999-10-20 | — | — | EP | disclosed |
| WO-1998025901-A1 | INDOLIN-2-ONE DERIVATIVES, METHOD FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SANOFI (FR) | 1998-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069496-A1 | 4-((PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS | PPARA, PPARG, PPARD | TSHR 302/4885TDP1 3670/4885L3MBTL1 3157/4885 |
| US-20250282771-A1 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | BCL2, BCL2L10, BCL2L1 | TSHR 3853/4885TDP1 1378/4885L3MBTL1 1268/4885 |
| US-20240238423-A9 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | BCL2A1, BCL2L1, BCL3 | TSHR 4074/4885TDP1 535/4885L3MBTL1 1066/4885 |
| US-20070142397-A2 | PHENYPIPERAZINE DERIVATIVES WITH A COMBINATION OF PARTIAL DOPAMINE-D2 RECEPTOR AGONISM AND SEROTONIN REUPTAKE INHIBITION | HTR2C, HTR2A, HTR5A | TSHR 162/4885TDP1 3442/4885L3MBTL1 3826/4885 |
| US-20230390404-A1 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | BCL2A1, BCL2L1, BCL3 | TSHR 4074/4885TDP1 535/4885L3MBTL1 1066/4885 |
| US-20250288683-A1 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | BCL2L1, BCL2, BCL2L10 | TSHR 3777/4885TDP1 930/4885L3MBTL1 977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.